NCCN has published the following updates to the Chronic Myelogenous Leukemia (CML) chapter of the NCCN Drugs & Biologics Compendium (NCCN Compendium™) to reflect updates to the preliminary 2011 version of the corresponding NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™):
This update includes dasatinib and nilotinib as alternatives to imatinib for the primary treatment of newly diagnosed, Philadelphia chromosome or BCR-ABL positive CML (category 1 designation). In addition, dasatinib and nilotinib have been included as follow-up therapy in patients who have had inadequate responses to first-line therapy with a different multikinase inhibitor (category 2A designation). These updates are based on FDA approval (for nilotinib) and on a preliminary teleconference with the NCCN Guidelines Panel for CML.
For the complete updated versions of the NCCN Guidelines™ and the NCCN Compendium™ please visit NCCN.org.